← Human Trials & Peer-Reviewed Studies
Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1)
Plain-language guide to PMID 41187967 (2026): double-blind randomized controlled trial study of Survodutide in 2 individuals.
Key Facts
- PMID
- 41187967
- Journal
- Diabetes, obesity & metabolism
- Year
- 2026
- Study type
- Randomized Controlled Trial
- Authors
- le Roux CW et al. (10 authors)
- DOI
- 10.1111/dom.70196
What This Study Did, in Plain Language
What Was Tested
Researchers studied Survodutide in this randomized controlled trial publication.
Two multinational phase 3 trials are investigating survodutide for obesity management in individuals with or without T2D.
The researchers report the baseline characteristics of participants in the SYNCHRONIZE-1 trial in adults with obesity without T2D (ClinicalTrials.gov: NCT06066515).
Who Took Part
According to the abstract, 2 individuals were involved.
By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
The individuals were allocated by chance, so the Survodutide group and the comparison group should start out alike.
Blinding on both sides kept the individuals and researchers unaware of who received Survodutide.
The comparison arm used a placebo, so changes seen with Survodutide could be set against what happens without it.
A time span of 76 weeks appears in the methods.
What Was Measured
The subject headings attached to it are Obesity, Weight Loss, Glucagon-Like Peptide-1 Receptor Agonists, Anti-Obesity Agents and Diabetes Mellitus, Type 2.
Author keywords: glucagon‐like peptide‐1 receptor agonists and randomized controlled trial.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Survodutide in 2 individuals over 76 weeks.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2026 (Diabetes, obesity & metabolism), a journal based in England.
More context: the Survodutide compound page, all human trials.
Our Notes on the Compound
Survodutide: An investigational long-acting GLP-1 and glucagon receptor dual agonist studied for obesity and metabolic liver disease.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.